Jesús Castilla

9.9k total citations · 1 hit paper
288 papers, 5.4k citations indexed

About

Jesús Castilla is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Jesús Castilla has authored 288 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 225 papers in Epidemiology, 121 papers in Infectious Diseases and 32 papers in Health. Recurrent topics in Jesús Castilla's work include Influenza Virus Research Studies (101 papers), Respiratory viral infections research (87 papers) and HIV/AIDS Research and Interventions (57 papers). Jesús Castilla is often cited by papers focused on Influenza Virus Research Studies (101 papers), Respiratory viral infections research (87 papers) and HIV/AIDS Research and Interventions (57 papers). Jesús Castilla collaborates with scholars based in Spain, United States and Italy. Jesús Castilla's co-authors include Iván Martínez‐Baz, Jorge del Romero, Carmen Ezpeleta, Marcela Guevara, Luís de la Fuente, Víctoria Hernando, Manuel Garcìa Cenoz, Ana Navascués, Aurelio Barricarte and Carmen Rodríguez and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Jesús Castilla

280 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

2024 43 citations Guillermo Ezpeleta, Ana Navascués et al. Vaccines profile →

Peers

Countries citing papers authored by Jesús Castilla

Since Specialization

Citations

This map shows the geographic impact of Jesús Castilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús Castilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús Castilla more than expected).

Fields of papers citing papers by Jesús Castilla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús Castilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús Castilla. The network helps show where Jesús Castilla may publish in the future.

Co-authorship network of co-authors of Jesús Castilla

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús Castilla. A scholar is included among the top collaborators of Jesús Castilla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús Castilla. Jesús Castilla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hospitalisation due to respiratory syncytial virus in a population-based cohort of older adults in Spain, 2016/17 to 2019/20 2025 ·Eurosurveillance ·(unknown), Camino Trobajo‐Sanmartín, Ana Navascués, (unknown), Itziar Casado, Carmen Ezpeleta, Jesús Castilla, Iván Martínez‐Baz	3
2	Absence of short-term changes in knowledge and attitudes among household contacts of COVID-19 cases during the post-acute phase of the pandemic in Catalonia and Navarre, Spain 2024 ·Frontiers in Public Health ·(unknown), Diana Toledo, (unknown), Pere Godoy, Manuel Garcìa Cenoz, Ignasi Parrón, Jesús Castilla, Ángela Domı́nguez, Iván Martínez‐Baz	0
3	Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study breakdown → 2024 ·Vaccines ·Guillermo Ezpeleta, Ana Navascués, (unknown), (unknown), S. Belloc, (unknown), Juan Carlos Muruzábal, Manuel Garcìa Cenoz, Camino Trobajo‐Sanmartín, (unknown), Iván Martínez‐Baz, (unknown), Itziar Casado, (unknown), Carmen Ezpeleta, Jesús Castilla	43
4	Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021–2022 2024 ·Vaccines ·Iván Martínez‐Baz, Camino Trobajo‐Sanmartín, Ana Miqueleiz, Nerea Egüés, Manuel Garcìa Cenoz, Itziar Casado, Ana Navascués, Miguel Fernández-Huerta, (unknown), Marcela Guevara, Carmen Ezpeleta, Jesús Castilla	2
5	Assessment of Knowledge and Attitudes Over Time in Postacute COVID-19 Environments: Protocol for an Epidemiological Study 2023 ·JMIR Research Protocols ·Iván Martínez‐Baz, (unknown), Núria Soldevila, Núria Torner, (unknown), Manuel Garcìa Cenoz, Glòria Pérez, Cristina Burgui, Jesús Castilla, Pere Godoy, Ángela Domı́nguez, Diana Toledo	2
6	Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022 2023 ·Eurosurveillance ·Iván Martínez‐Baz, Camino Trobajo‐Sanmartín, Ana Miqueleiz, Itziar Casado, Ana Navascués, Cristina Burgui, Carmen Ezpeleta, Jesús Castilla, Marcela Guevara, (unknown)	16
7	Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023 2023 ·Vaccines ·Iván Martínez‐Baz, Miguel Fernández-Huerta, Ana Navascués, Francisco Pozo, Camino Trobajo‐Sanmartín, Itziar Casado, (unknown), Carmen Ezpeleta, Jesús Castilla	6
8	Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022 2022 ·Eurosurveillance ·Jesús Castilla, (unknown), (unknown), (unknown), Ana Miqueleiz, Camino Trobajo‐Sanmartín, Ana Navascués, Iván Martínez‐Baz, Itziar Casado, Cristina Burgui, Nerea Egüés, Guillermo Ezpeleta, Carmen Ezpeleta	15
9	Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts 2022 ·Postgraduate Medicine ·Iván Martínez‐Baz, Camino Trobajo‐Sanmartín, Cristina Burgui, Itziar Casado, Jesús Castilla	14
10	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants 2022 ·Microbiology Spectrum ·Camino Trobajo‐Sanmartín, Iván Martínez‐Baz, Ana Miqueleiz, Miguel Fernández-Huerta, Cristina Burgui, Itziar Casado, (unknown), Ana Navascués, Jesús Castilla, Carmen Ezpeleta	25
11	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021 2021 ·Eurosurveillance ·Iván Martínez‐Baz, Camino Trobajo‐Sanmartín, Ana Miqueleiz, Marcela Guevara, Miguel Fernández-Huerta, Cristina Burgui, Itziar Casado, María Eugenia Portillo, Ana Navascués, Carmen Ezpeleta, Jesús Castilla, (unknown)	49
12	Self-Collection of Saliva Specimens as a Suitable Alternative to Nasopharyngeal Swabs for the Diagnosis of SARS-CoV-2 by RT-qPCR 2021 ·Journal of Clinical Medicine ·Camino Trobajo‐Sanmartín, (unknown), Ana Navascués, María Jesús Guembe, (unknown), Jesús Castilla, Carmen Ezpeleta	12
13	Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain 2021 ·International Journal of Environmental Research and Public Health ·Jesús Castilla, Ujué Fresán, Camino Trobajo‐Sanmartín, Marcela Guevara	4
14	Quality of life in people living with HIV in Romania and Spain 2021 ·BMC Infectious Diseases ·Meaghan Kall, Ujué Fresán, (unknown), Graham Brown, Cristina Burgui, Jesús Castilla, (unknown), (unknown), Valérie Delpech, Jeffrey V. Lazarus	14
15	Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers 2020 ·Vaccines ·Iván Martínez‐Baz, Camino Trobajo‐Sanmartín, (unknown), Ana Navascués, (unknown), (unknown), Ujué Fresán, Carmen Ezpeleta, Jesús Castilla	29
16	Comparison of clinical features and diagnosis between the A and B subgroups of respiratory syncytial virus. 2017 ·Anales del Sistema Sanitario de Navarra ·(unknown), Laura Moreno‐Galarraga, (unknown), (unknown), (unknown), Marc Díez, (unknown), Jesús Castilla	0
17	Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C 2017 ·Anales del Sistema Sanitario de Navarra ·(unknown), José Manuel Zozaya, Jesús Repáraz, Jesús Castilla, (unknown), (unknown), (unknown), Ramón San Miguel	7
18	Factores de riesgo de hospitalización por gripe (H1N1) 2009 y efectividad de intervenciones farmacológicas y no farmacológicas en su prevención. Estudio de casos y controles 2011 ·SHILAP Revista de lepidopterología ·Fabiola Domínguez, Jordi Alonso, Jenaro Astray, Maretva Baricot, Rafael Cantón, Jesús Castilla, Ady Castro, (unknown), Pere Godoy, Fernando Gónzález‐Candelas, Vicente Martín, José María Mayoral, José M. Quintana, (unknown), Tomàs Pumarola, Núria Soldevila, Sonia Tamames	10
19	Evaluación del sistema de información de Navarra sobre diagnósticos de infección por el VIH, 1985-2003 2007 ·Revista Española de Salud Pública ·Ana María Caro-Murillo, Concepción Moreno-Iribas, F. Irisarri, (unknown), (unknown), (unknown), Jesús Castilla	4
20	[The treatment of chronic hepatitis C with interferon in patients infected with the human immunodeficiency virus. The Spanish Group for the Study of Viral Hepatitis in HIV+ Patients]. 1996 ·PubMed ·Vincent Soriano, Javier García‐Samaniego, R. Bravo, Jorge González, (unknown), (unknown), (unknown), E. Carballo, (unknown), Jesús Castilla, (unknown), (unknown), Jorge del Romero, J. Pedreira, Juan González‐Lahoz	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact